Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
This image was generated by AI and may not depict real events.
Novo Nordisk has partnered with OpenAI to integrate AI across its R&D, manufacturing, and corporate functions. The partnership aims to bring new treatment options to patients faster by analyzing complex datasets and identifying promising drug candidates.
Novo Nordisk has teamed up with OpenAI to deploy AI globally. The partnership will involve using AI to analyze complex datasets and identify promising drug candidates. This will help cut R&D timelines and bring new treatment options to patients faster. The collaboration will also seek efficiencies in manufacturing and corporate functions. Novo Nordisk will ensure strict data protection and human oversight. The company aims to update investors on its progress during its first-quarter earnings presentation on May 6.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.